|

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

RECRUITINGPhase 1/2Sponsored by Eisbach Bio GmbH
Actively Recruiting
PhasePhase 1/2
SponsorEisbach Bio GmbH
Started2024-09-09
Est. completion2027-09
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06525298

Summary

This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Recurrent locally advanced or metastatic solid tumors
* Homologous recombination deficient mutations
* Progressed on at least on prior line of treatment or intolerant to additional effective standard therapy
* Measurable disease (RECIST 1.1 Criteria)
* Adequate organ and bone marrow function
* ECOG Performance Status 0 or 1
* Life expectancy \> 3 months

Exclusion Criteria:

* History or evidence of any clinically relevant gastrointestinal disease
* Radiation therapy within ≤2 weeks
* Significant cardiovascular disease
* Uncontrolled, active, symptomatic brain metastases

Conditions4

Advanced Solid TumorCancerHRR DeficiencyHomologous Recombination Deficiency

Locations1 site

MD Anderson Cancer Center
Houston, Texas, 77030
Timothy Yap713-563-1784TYap@mdanderson.org

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.